K252a

Molecular Formula:

C27H21N3O5

CAS number:

99533-80-9

EU number:

640-127-4

Fermentek product code:

Source:

Nocardiopsis sp

Brand/grade:

For research

Specifications

Appearance:

White to pale yellow powder

Purity by HPLC:

≥98% ; refer to CoA for more data

Purity By TLC:

≥98% ; refer to CoA for more data

Melting point:

255°C-270°C

Solubility test:

Clear colorless to slight yellow solution at 50mg/ml of DMSO

Chemical identification

Names and identifiers:

RTECS NZ0550000

Description:

K252a: Cell permeable protein kinase inhibitor

Molecular weight:

467.47

InChl Key:

KOZFSFOOLUUIGY-IYYJOCMQSA-N

Canonical SMILES:

CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(C(=O)OC)O

Isomeric SMILES:

C[C@]12[C@@](C[C@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(C(=O)OC)O

Further Information

Solubility ( literature ):

Readily soluble in chloroform, acetonitrile, acetone, dioxane, tetrahydrofuran, pyridine;soluble in ethanol, methanol, 1-propanol, ethyl acetate and n-butanol; insoluble in water, 2-propanol

Compound Classification:

indolocarbazole alkaloid
PK inhibitor

Storage, handling:

Store in a freezer upon arrival, at -10°C to -25°C

Protect from moisture

Protect from light !

Use the original container to store the product.

Keep the lid tightly closed.

Expiration time:

Applications:

K252a is a highly potent cell permeable inhibitor of CaM kinase and phosphorylase kinase . At high concentrations it also inhibitors of serine/threonine protein kinases. K252a inhibits tyrosine phosphorylation of Trk A induced by NGF K252a is reported to promote myogenic differentiation in C2 mouse myoblasts

Disclaimer:

For Research use only

Not for Human or Drug use

Not extracted from humans or animals

Refer to MSDS for further safety and handling instructions

Composition

Ingredient type:

Fermentek product

Publications

WO Application WO2017053983A1 Quantifying met protein for cancer treatment ;
Anti-cancer therapeutic agents designed to specifically inhibit the function and/or reduce the presence of the Met protein include: MET kinase inhibitors such as K252a (Fermentek Biotechnology)

US Patent Application for MODULATORS OF CELL DEATH PROCESSES Patent Application (Application #20180071280).
URIFER LTD; Inventors: Yoav ELKIS, Sally SHPUNGIN, Uri NIR